An invalid vocabulary is selected. Please change it in the options.
Title Creditssort descending Start date - Expiration date
Multigene and Biomarker Testing in Breast Cancer 1.00 03/15/2024 - 12:00am to 03/15/2025 - 12:00am
NCCN Guidelines® Insights - Biliary Tract Cancers, Version 2.2023 1.00 07/10/2023 - 12:00am to 07/10/2024 - 12:00am
Recorded Presentation from the NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer 1.00 06/09/2023 - 12:00am to 05/31/2024 - 12:00am
Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates 1.25 03/15/2024 - 12:00am to 03/15/2025 - 12:00am
Locoregional Management of Breast Cancer with SABCS Updates 1.25 03/15/2024 - 12:00am to 03/15/2025 - 12:00am
Advances in the Management of Metastatic Castration-Resistant Prostate Cancer: Expert Guidance and Resources for the Interdisciplinary Team 1.25 12/21/2023 - 12:00am to 12/21/2024 - 12:00am
What Drives Reimbursement for Biomarker Testing? 1.25 06/15/2023 - 12:00am to 06/15/2024 - 12:00am
The Evolving Landscape in CLL/SLL: Best Practice Clinical Applications of Current Evidence and New Guideline Recommendations 1.75 07/21/2023 - 12:00am to 07/21/2024 - 12:00am
Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes 1.75 07/21/2023 - 12:00am to 07/21/2024 - 12:00am
Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future 1.75 07/21/2023 - 12:00am to 07/21/2024 - 12:00am
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors 1.75 08/09/2023 - 12:00am to 08/09/2024 - 12:00am
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2.00 12/21/2023 - 12:00am to 12/21/2024 - 12:00am

Pages